Now the oral drug is getting a second chance at Kura Oncology, a new San Diego biopharmaceutical company led by Troy Wilson, a serial life sciences entrepreneur. Kura is springing onto the scene as a fully formed public company, after Wilson secured a $60 million investment accompanied by a reverse merger—an unusual route that enables Kura to publicly list its shares as quickly as possible.
Wilson wants to apply the concepts of “precision medicine” to determine if tipifarnib can be used to treat some people with certain types of AML and solid tumor cancers. The drug was shelved before advances in genomic sequencing, which are now being applied to help drug researchers identify the gene...
Also read: Air bag maker Takata declares bankruptcy